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Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability in the
penis and its supplying vasculature, resulting in vasodilation and increased blood flow. PDE5Is might benefit car-
diovascular diseases because phosphodiesterase-5 is also located elsewhere in the body, including the pulmo-
nary and systemic vasculature and in hypertrophied myocardium. PDE5Is are approved for pulmonary arterial
hypertension, given that they improved several hemodynamic and clinical parameters in large randomized trials.
Initial evidence suggests that PDE5Is benefit patients with congestive heart failure and secondary pulmonary
hypertension. PDE5Is seem to improve hemodynamic and clinical parameters in patients with high-altitude pul-
monary edema (HAPE) and high-altitude pulmonary hypertension. In climbers with prior episodes of HAPE,
PDE5Is prevented HAPE in 2 small randomized trials. In small randomized trials of PDE5Is, patients with Ray-
naud’s phenomenon demonstrated improved blood flow, fewer symptoms and frequency of attacks, and resolu-
tion of digital ulcers. In addition to enhancing vasodilation, PDE5Is seem to protect the myocardium through
complex pathways that involve nitric oxide, cyclic guanosine monophosphate, protein kinase G, extracellular-
signal-regulated kinase, B-cell lymphoma protein-2, and Rho kinase inhibition. In animal models of acute myo-
cardial infarction, PDE5Is consistently reduced infarct size indicating cardioprotection and PDE5Is also promote
reverse remodeling and reduce myocardial apoptosis, fibrosis, and hypertrophy. PDE5Is might also benefit pa-
tients with treatment-resistant hypertension, preeclampsia, or peripheral arterial disease. This review presents
the pathophysiology and trial data with regard to the use of PDE5Is for cardiac diseases. (J Am Coll Cardiol
2012;59:9–15) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.051Phosphodiesterase-5 inhibitors (PDE5Is) are widely used
for erectile dysfunction, making sildenafil and tadalafil
among the 75 most popular prescription drugs dispensed in
the United States. Phosphodiesterase type 5 (PDE5), how-
ever, is not confined to the human penis; it is found
elsewhere in the body, including the pulmonary and sys-
temic vasculature and in hypertrophied myocardium. In
fact, the PDE5I sildenafil was originally investigated for its
potential in treating angina. The PDE5Is demonstrated
only marginal benefit for angina in clinical trials, but
patients did demonstrate the peculiar “side effect” of im-
proved erections. After extensive clinical trials and years of
experience in treating erectile dysfunction, PDE5Is now
have a proven safety record: they do not increase cardiovas-
cular events (even in patients with coronary artery disease or
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accepted July 25, 2011.congestive heart failure) and are safe in combination with
most other medications (contraindicated with all nitrates,
use with caution with alpha-blockers, might require dose
adjustments with drugs that alter the cytochrome P450 3A4
metabolic pathway) (1). Reviewed elsewhere (2), sildenafil
and tadalafil have been approved for use in patients with
pulmonary arterial hypertension (PAH) and are now pre-
scribed as first-line therapy for many such patients. Initial
investigation suggests that PDE5Is might benefit other
cardiovascular diseases, including congestive heart failure
(CHF), myocardial infarction, altitude sickness, hyperten-
sion, and Raynaud’s phenomenon. This review will explore
the data and theory with regard to the use of PDE5Is in
cardiovascular diseases other than PAH.
Mechanism of Action
Vascular tone and blood flow is primarily regulated by
endothelial-dependent vasodilation whereby endothelial
cells produce nitric oxide (NO) that diffuses to the adjacent
smooth muscle cells and enhances the production of cyclic
guanosine monophosphate (cGMP), which relaxes smooth
muscle, resulting in vasodilation. The cGMP is broken
down by PDE5; thus, PDE5Is inhibit the breakdown of
cGMP, resulting in enhanced vasodilation. By taking advan-
tage of PDE5 located within the systemic and pulmonary
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fit cardiovascular diseases. In ad-
dition to enhancing vasodilation,
PDE5Is protect myocytes di-
rectly through complex mecha-
nisms described in the following
text.
CHF
The PDE5Is improved hemody-
namic and clinical parameters in
patients with CHF in a number of
small trials (Table 1), although
efficacy has not been tested in
large-scale, long-term placebo-
controlled trials. In small placebo-
controlled trials of patients with
CHF, sildenafil increased oxygen
uptake (3,4), increased cardiac in-
dex (4,5), reduced systemic vascu-
lar resistance (5), reduced aorta
stiffness (5), and improved exercise
time (3), 6-min walk distance (4),
depression scores (6), and quality of life (6). The hemodynamic
mprovements of Sildenafil were maintained at 4 weeks (7),
nd the benefits of sildenafil on pulmonary arterial pressure,
reathlessness score, and aerobic efficiency persisted at 6
onths with a trend to greater improvement (8).
Small trials in patients with CHF demonstrated the
reatest benefit of PDE5Is in patients with secondary PAH
nd right ventricular failure (4,9). The utility of PDE5Is in
HF patients without PAH is less clear, emphasizing the
ack of large-scale testing.
In normal myocardium the presence of PDE5 is minimal
o none. PDE5 expression, however, seems to be increased
n a number of myocardial disease states, including chronic
yopathies involving myocyte or ventricular hypertrophy.
istologic examination of myocardium from 6 patients with
Abbreviations
and Acronyms
Bcl-2  B-cell lymphoma
protein-2
cAMP  cyclic adenosine
monophosphate
cGMP  cyclic guanosine
monophosphate
CHF  congestive heart
failure
HAPE  high-altitude
pulmonary edema
HAPH  high-altitude
pulmonary hypertension
NO  nitric oxide
PAH  pulmonary arterial
hypertension
PDE5 
phosphodiesterase-5
PDE5I 
phosphodiesterase-5
inhibitor
PDE5Is for CHFTable 1 PDE5Is for CHF
Ref. # Patients (n) Design PDE5
(4) 34 CHF and PAH Randomized, placebo Sildena
(3) 23 CHF Crossover, placebo Sildena
(5) 20 EF 35% Crossover, placebo Sildena
(8) 46 CHF Randomized, placebo Sildena
(7) 19 CHF Randomized, placebo Sildena
(6) 35 CHF Crossover, placebo Sildena
(9) 22 CHF and PAH, 24 CHF no PAH Prospective SildenacGMP  cyclic guanosine monophosphate; CHF  congestive heart failure; EF  ejection fraction; PAH HF and 6 normal donor hearts revealed PDE5 within the
yocardium only in CHF hearts (10). Myocardial PDE5
xpression correlated with markers of oxidative stress (10).
n mouse (10) and rat (11) models, pressure overload
esulted in increased myocardial PDE5 levels. Superoxide
ismutase blunted the increase in PDE5 and protected
gainst left ventricular hypertrophy and CHF, suggesting
hat oxidative stress increases PDE5 expression leading to
ypertrophy (10). In human surgical specimens, PDE5 was
ot expressed in normal myocardium; however, PDE5 and
DE5 messenger ribonucleic acid was upregulated in hy-
ertrophied myocardium, but only in the chamber with
ressure overload (11). Furthermore, sildenafil increased the
ontractility of hypertrophied myocytes in cell-shortening
xperiments and in hypertrophied right ventricles in a
angendorff model (11).
PDE5Is increase cGMP levels, which under normal
ircumstances would activate protein kinase G, decrease
ntracellular calcium levels, and reduce contractility. How-
ver, in hypertrophied myocardium, protein kinase G activity
s inhibited, so cGMP preferentially shifts to its other pathway:
nhibition of phosphodiesterase-3 (11). Thus, in hypertrophied
yocardium, PDE5Is increase cGMP—which inhibits phos-
hodiesterase-3—thereby increasing cyclic adenosine mono-
hosphate (cAMP), which activates protein kinase A; this, in
urn, increases intracellular calcium and contractility (11).
Sildenafil seems to induce additional mechanisms that
revent adverse remodeling (12). To assess the effects of
ildenafil on remodeling independent of infarct size, ran-
omized treatment began 3 days after permanent coronary
cclusion in a mouse model of myocardial infarction (12).
ompared with placebo, sildenafil preserved left ventricular
unction and reduced left ventricular dilation. Mice ran-
omized to sildenafil demonstrated significantly less fibro-
is, apoptosis, and ventricular hypertrophy. Moreover, silde-
afil increased protein kinase G activation (from increased
O availability and cGMP levels), increased the Bcl-2/Bcl-
–associated X protein ratio, and inhibited the RhoA/Rho-
Main Outcomes
Improved oxygen uptake, pulmonary vascular resistance, cardiac output, and
exercise capacity. Improvements correlated with baseline pulmonary vascular
resistance and inversely with baseline right ventricular ejection fraction.
Improved peak oxygen uptake and exercise time.
Improved cardiac index, systemic vascular resistance, and large artery stiffness.
Improved pulmonary arterial pressure, breathlessness score, and aerobic
efficiency through 6 months.
Improved pulmonary arterial pressure, maximal oxygen uptake, ventilator
efficiency, and oxygen uptake kinetics.
Improved depression scores, quality of life.
Patients with high pulmonary vascular resistance had low cGMP, low pulmonary
and systemic artery compliance, and low cardiac index. Sildenafil improved
pulmonary vascular resistance, systemic vascular resistance, cardiac index,
and pulmonary artery compliance.I
fil
fil
fil
fil
fil
fil
filpulmonary arterial hypertension; PDE5I  phosphodiesterase-5 inhibitor.
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G inhibitor). The Rho kinase pathway is pathogenic, and
Rho kinase inhibition has previously improved atheroscle-
rosis, post-infarction remodeling, and cardiac hypertrophy
(12). The authors concluded that sildenafil reduced myo-
cardial apoptosis, fibrosis, and hypertrophy through a mech-
anism that involves protein kinase G activation, Rho kinase
inhibition, and increased Blc-2 (anti-apoptotic, see follow-
ing text) (12).
Further evidence of sildenafil’s benefits on reverse remod-
eling comes from a mouse model of cardiomyopathy in-
duced by pressure overload with aortic banding (13). De-
spite sustained pressure overload, sildenafil reversed pre-
established maladaptive responses to pressure overload,
including eccentric remodeling, maladaptive molecular sig-
naling, hypertrophy, fibrosis, and depression of function
(13,14). In addition, sildenafil improved endothelial-
mediated vasodilation in patients with CHF (15).
In conclusion, in patients with CHF, sildenafil improves
numerous hemodynamic and clinical parameters both
acutely and chronically. In experimental models, sildenafil
also benefits cardiac remodeling, apoptosis, fibrosis, and
hypertrophy. The heterogeneous nature of CHF requires
large scale, long-term placebo-controlled trials with clinical
endpoints to determine efficacy. To date, no studies pow-
ered to assess mortality have been completed, and the
clinical utility of PDE5Is in CHF remains unclear.
Doxorubicin Cardiotoxicity
In a model of chronic (8 weeks) doxorubicin cardiotoxicity,
sildenafil protected against doxorubicin-induced apoptosis
and preserved left ventricular function (16). In a mouse
model, compared with doxorubicin alone, treatment with
doxorubicin plus tadalafil significantly improved survival,
fractional shortening, ejection fraction, and hypertrophy
(17). Moreover, tadalafil reduced the incidence of apoptosis
and preserved the expression of Bcl-2, which blocks the
mitochondrial pathway of apoptosis. Tadalafil also increased
cardiac cGMP levels and protein kinase G activity, upregu-
lated mitochondrial superoxide dismutase, and prevented
lipid peroxidation. The authors concluded that “tadalafil
activated mitochondrial antioxidative and anti-apoptotic
mechanisms through up-regulation of cGMP, protein ki-
nase G activity, and mitochondrial superoxide dismutase
level without interfering with the chemotherapeutic benefits
of doxorubicin” (17). Therefore, prophylactic PDE5Is for
patients treated with doxorubicin seems promising and
deserves further clinical investigation.
Cardioprotection
Mechanisms similar to those involved in preventing doxo-
rubicin cardiotoxicity also seem to protect the heart from
acute infarction, as reviewed elsewhere (18). Briefly, NO
synthesis by endothelial- and especially inducible-NO syn-
thase is an essential component of cardioprotection (19,20).Numerous stimuli, including PDE5Is, initiate the NO
synthase signaling cascade by first activating protein kinase
C or extracellular-signal-regulated kinase, which mediates
survival pathways in many cell types—including the delayed
cardioprotective effect of sildenafil (18). Nitric oxide directly
mediates early cardioprotection (21–24) and also triggers
delayed cardioprotection by increasing cGMP levels and
protein kinase G activity (25–27). Mitochondrial adenosine
triphosphate (ATP)-dependent potassium channels are a
critical downstream target of cardioprotection pathways.
Mitochondrial integrity is essential to cell survival, by
maintaining ATP synthesis and calcium homeostasis. Nitric
oxide acts directly and indirectly through protein kinase G
to open mitochondrial ATP potassium channels, which
protect myocytes by compensating for the altered membrane
potential and enabling protons to be pumped out of the
mitochondria, which maintains the electrochemical gradient
necessary for ATP synthesis and calcium transport (18).
Additionally, PDE5Is also seem to promote cardioprotec-
tion through NO-dependent up-regulation of Bcl-2, which
promotes cell survival by inhibiting the mitochondrial per-
meability transition pore (18).
Numerous studies have reported a reduction in infarct
size in animals treated with sildenafil compared with pla-
cebo (19–22,25,26). Sildenafil provided cardioprotection
when administered immediately (25), 30 min (21), 24 h
(21,22), or chronically for 4 weeks (19) before a coronary
occlusion or during coronary reperfusion (26). Likewise,
tadalafil (27,28) and vardenafil (24) reduced infarct size
when given 30 to 120 min before coronary occlusion. The
duration of cardioprotection from tadalafil remained until
36 to 40 h after a single dose, and repeat administration at
36 and 72 h extended protection until 108 h (23). In
addition to reducing infarct size, administration of PDE5Is
before coronary occlusion in animal models increased
endothelial- and inducible-NO synthase, (19,20) reduced
cardiac hypertrophy (19), reduced apoptosis (19), preserved
fractional shortening (27), and improved survival (19,27). In
a dog model mimicking cardiopulmonary bypass, vardenafil
improved recovery of the ventricular end-systolic pressure
volume relationship, increased coronary blood flow, and
preserved endothelial function (29). At least 1 study reported
that sildenafil had no effect on infarct size but did improve
coronary vascular resistance and certain hemodynamic param-
eters during experimental myocardial infarction (30).
High-Altitude Pulmonary Edema
and High-Altitude Pulmonary Hypertension
High altitudes can cause pulmonary disease acutely (high-
altitude pulmonary edema [HAPE]) and chronically (high-
altitude pulmonary hypertension [HAPH]). Upon ascent
to altitudes 2,500 m, the lungs respond to hypoxia by
reducing NO availability, which precipitates pulmonary
artery vasoconstriction and increased pulmonary artery pres-
sure. Depending upon altitude and ascent rate, 0.1% to 4%
H
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and restricted gas exchange (31,32). In populations living at
3,200 m, HAPH occurs in 5% to 18% (33). At high
altitudes, sustained hypoxia can lead to pulmonary endothe-
lial dysfunction, muscularization, and deposition of connec-
tive tissue in the pulmonary arteries and PAH leading to
right ventricular hypertrophy and potentially culminating in
right heart failure and premature death. The PDE5Is seem
ideally suited to prevent and treat HAPE and HAPH,
because PDE5Is increase NO availability, improve endo-
thelial function, and reduce pulmonary arterial resistance
and pressure (Table 2).
In fact, in climbers with a history of HAPE, prophylactic
tadalafil significantly and markedly reduced the incidence of
HAPE compared with placebo in 2 separate studies (34,35).
In 10 healthy volunteers, sildenafil almost abolished the
56% increase in pulmonary arterial pressure induced by
breathing 11% oxygen for 30 min (36). Sildenafil was
investigated in 10 trained male cyclists studied at sea-level
and at simulated high altitude (breathing 12.8% oxygen)
(37). At sea-level, sildenafil did not affect any hemodynamic
or performance parameters. In contrast, while breathing
12.8% oxygen sildenafil increased stroke volume, cardiac
output, and arterial oxygen saturation during set-work-rate
exercise, and sildenafil lowered 6-km time-trial time by 15%
(37). Sildenafil was investigated in 14 healthy volunteers
assessed at rest and during maximal exercise capacity while
breathing 10% oxygen both at low altitude and at high
altitude (Mount Everest base camp) (38). At low altitude,
sildenafil increased oxygen saturation during exercise, re-
duced systolic pulmonary arterial pressure during rest and
exercise, and increased maximum workload (38). At high
altitude, sildenafil had no effect on oxygen saturation at rest
but did reduce pulmonary arterial pressure during rest and
exercise and increased maximum workload and cardiac
output. Thus, sildenafil and tadalafil seem to reduce pulmo-
nary arterial pressure, increase maximum workload, and
PDE5Is for HAPE and HAPHTable 2 PDE5Is for HAPE and HAPH
Ref. # Patients (n) Design PDE5I
(34) 29 with prior HAPE Randomized, placebo Tadalafil
(35) 23 with prior HAPE Randomized, placebo Tadalafil
(37) 10 trained cyclists Randomized, crossover Sildenafil
(38) 14 volunteers Crossover, placebo Sildenafil
(36) 10 volunteers Randomized, placebo Sildenafil
(36) Mice Prospective Sildenafil
(39) 22 HAPH Randomized, placebo SildenafilHAPE  high-altitude pulmonary edema; HAPH  high-altitude pulmonary hypertension; other abbreviatreduce the incidence of HAPE, during exercise while
breathing air with reduced oxygen content and during
ascent to high altitude.
To investigate sildenafil as a therapy for HAPH, 689
subjects living 2,500 m were screened by examination and
electrocardiogram, revealing 188 subjects (27%) with right
ventricular hypertrophy, of which 44 underwent cardiac
catheterization (39). Twenty-nine of 44 subjects (66%) had
resting mean pulmonary arterial pressure 25 mm Hg.
Twenty-two of these patients with HAPH were then
randomized to placebo or sildenafil. Sildenafil reduced
pulmonary arterial pressure and improved 6-min walk dis-
tance, after 12 weeks of therapy (39). Moreover, sildenafil
reduced right ventricular systolic pressure, reduced right
ventricular hypertrophy, and inhibited pulmonary vascular
remodeling, in mice given placebo or sildenafil for 3 weeks
during exposure to 10% oxygen (36). In cultured human
pulmonary artery smooth muscle cells exposed to platelet-
derived growth factor, sildenafil reduced smooth muscle cell
proliferation and DNA synthesis through pathways involv-
ing cGMP, protein kinase G, cAMP (sildenafil increased
cAMP through cGMP inhibition of phosphodiesterase type 3),
and protein kinase A (40). In conclusion, initial evidence
suggests that PDE5Is might prevent and improve HAPE
and HAPH.
Hypertension
Effects of PDE5I on systemic vascular resistance might be
useful for treating patients with hypertension. This was
investigated in 25 patients with untreated hypertension
randomized to placebo or sildenafil 50 mg 3 daily (41).
Sildenafil decreased average daytime blood pressure (by
8/6 mm Hg) and clinic blood pressure (by 5/5 mm
g) (41). Numerous studies of PDE5Is in a variety of
atients generally reported only small reductions in blood
ressure (Table 3) (1). In most healthy subjects, blood
Main Outcomes
HAPE in 7/9 placebo; 1/8 tadalafil (p  0.007); smaller increase in pulmonary
arterial pressure at high altitude
At high altitude, did not improve maximum oxygen uptake, oxygen saturation, or
pulmonary arterial pressure but decreased incidence of HAPE (7/8 placebo;
1/7 tadalafil; dexamethasone 0/8; p  0.001)
At sea-level, no effect on cardiovascular or performance parameters; on 12.5%
oxygen, increased stroke volume, cardiac output, arterial oxygen saturation and
shortened 6-km time-trial time by 15%
At low altitude, improved oxygen saturation during exercise and pulmonary arterial
pressure during rest and exercise; at high altitude, reduced pulmonary arterial
pressure at rest and exercise, increased cardiac output and maximum workload
Almost abolished the 56% increase in pulmonary arterial pressure induced by
breathing 11% oxygen
For 3 weeks during exposure to 10% oxygen, reduced pulmonary arterial pressure
and right ventricular hypertrophy and inhibited pulmonary vascular remodeling
Reduced pulmonary arterial pressure and improved 6-min walk distanceions as in Table 1.
i
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administration (42), so multiple daily dosing would be
necessary and would not cover the morning rise in blood
pressure. Longer-acting tadalafil decreased diastolic blood
pressure for 12 h but did not affect systolic blood pressure in
healthy volunteers (43).
Although PDE5Is are contraindicated with any nitrate
medication, because of potentially severe hypotension, this
drug combination might be beneficial for patients with
treatment-resistant hypertension and was investigated in a
crossover trial including 6 such subjects continued on their
previous medications (44). Compared with sildenafil alone
and with isosorbide mononitrate alone, the combination of
sildenafil and isosorbide mononitrate produced the largest
blood pressure decrease (placebo-subtracted maximum de-
crease 26/18 mm Hg) without significant side effects
(44). The combination of PDE5Is and nitrates requires
further investigation to ensure safety.
Raynaud’s Phenomenon
The effects of PDE5Is on systemic vasodilation and
endothelial function might benefit patients with Ray-
naud’s phenomenon. In an open-label pilot study in 40
patients with Raynaud’s disease, vardenafil 10 mg twice
daily improved digital blood flow in 70% of patients and
improved clinical symptoms in 68% (45). In a crossover
study, sildenafil reduced the frequency and duration of
Raynaud’s attacks and markedly increased capillary blood
flow velocity (46). Moreover, visible healing was noted in
all 6 patients with chronic digital ulcerations, all 16
patients correctly identified the double-blinded pills as
either sildenafil or placebo, and 89% of patients requested
to continue sildenafil as off-label therapy after the con-
clusion of the study (46). Furthermore, in 19 patients
with systemic sclerosis and digital ulcers refractory to
Blood Pressure Reductions With PDE5IsTable 3 Blood Pressure Reductions With PDE5Is
Sildenafil Vardenafil Tadalafil
Healthy control subjects 10/7* 7/8† 0/5‡
Patients with stable coronary artery disease 9/8‡ 7/4‡
Patients with hypertension
With amlodipine 8/7§ 1/1§
With slow-release nifedipine 6/5†
With enalapril 4/1†
With metoprolol 7/4†
With bendrofluazide 6/4†
With angiotensin II receptor blocker 8/4§
With 1 or more antihypertensive
medications
4/2† 5/4‡
With multiple antihypertensive
medications
4/1†
Numbers are the change in systolic/diastolic blood pressure in mm Hg; “”  decreased; “” 
ncreased. *Mean maximum decrease from baseline. †Mean decrease from baseline relative to
lacebo. ‡Mean decrease from baseline. §Meanmaximum decrease relative to placebo. Including
diuretics, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers,
and calcium antagonists. Table adapted, with permission, from Schwartz and Kloner (1).
PDE5I  phosphodiesterase-5 inhibitor.treatment, the number of digital ulcers decreased from
3.1 to 1.1 ulcers/patient during sildenafil therapy for a
mean of 5.2 months (47). Approximately one-half of
patients developed new ulcers during sildenafil therapy,
suggesting that sildenafil does not prevent new ulcer-
ations (47). Previously, bosentan, an endothelin-1 recep-
tor antagonist, failed to heal digital ulcers but was
effective in preventing them (47). Thus, different mech-
anisms might be involved in preventing and healing
digital ulcers, and combination therapy might be benefi-
cial. Two other crossover studies did not demonstrate a
benefit with tadalafil therapy; however, it was noted that
placebo response was a factor (48,49). In a double-blind,
randomized study accepted for publication, sildenafil
significantly reduced the frequency of Raynaud’s attacks
compared with placebo (50). In conclusion, PDE5Is are
promising for the treatment of Raynaud’s patients, and
additional placebo-controlled trials are needed to clarify
dosing and subsets of patients most likely to benefit from
PDE5I therapy.
Other Cardiovascular Uses
The PDE5Is are hypothesized to benefit but have not been
tested in preeclampsia (51) and in patients undergoing
cardiac surgery (52). Sildenafil (53) and vardenafil (54) were
each studied in a mouse model of unilateral hindlimb
ischemia mimicking peripheral arterial disease. In each
study, the PDE5I enhanced ischemia-induced angiogenesis
as measured by vascular perfusion, tissue blood flow and
vascular density (53,54).
Conclusions
PDE5 is expressed throughout the human body, including
the pulmonary and systemic vasculature and hypertrophied
myocardium. The effects of PDE5Is on pulmonary circula-
tion and the hypertrophied right ventricle have made these
agents first-line therapy for many patients with PAH. The
PDE5Is also benefit hemodynamic and clinical parameters
in patients with CHF, especially those with secondary PAH
and right ventricular failure. The clinical utility of PDE5Is
in CHF patients requires large-scale clinical testing. The
PDE5Is are ideally suited for and have demonstrated benefit
in preventing and treating HAPE and HAPH. Cardiopro-
tection has been reported in numerous animal models where
PDE5Is reduced infarct size. In some but not all random-
ized trials, PDE5Is improved clinical parameters in patients
with Raynaud’s phenomenon. The PDE5Is might be ben-
eficial in combination with nitrates in patients with
treatment-resistant hypertension if proven to be safe. Mech-
anisms of benefit of PDE5Is include pulmonary and sys-
temic vasodilation, increased myocardial contractility, im-
proved endothelial function, and reduced apoptosis, fibrosis,
and hypertrophy through mechanisms involving NO,
cGMP, protein kinase G, Bcl-2, and Rho kinase inhibition.
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conditions described and might discover a benefit of
PDE5Is in other cardiovascular diseases.
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